About
Rezolute Inc (NASDAQ:RZLT) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 21 2026
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
Mar 24 2026
Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
Mar 4 2026
Rezolute to Participate in the Citizens Life Sciences Conference
Feb 12 2026
Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
Feb 4 2026
Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Financials
Revenue
$0
Market Cap
$349.3 M
EPS
-0.93
Translate